Ivabradine Doc Generici (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Inhibition of this current slows the depolarisation rate, leading to a reduction in heart rate without affecting contractility or blood pressure.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate strength, frequency and any necessary adjustments during therapy.

Safety data for ivabradine during pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Ivabradine Doc Generici, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s comorbidities.

Ivabradine tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Ivabradine is taken orally, usually as a tablet swallowed whole with a glass of water. It is generally administered with or without food, as directed by the prescriber, and should be taken at the same times each day to maintain consistent blood levels.

The most serious adverse events include severe bradycardia, atrial fibrillation or other arrhythmias, and visual disturbances such as luminous phenomena or persistent loss of vision. Patients should report any symptoms of fainting, palpitations, or visual changes promptly to their healthcare provider.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, sinoatrial block, or resting heart rates below 50 beats per minute. Caution is also advised for individuals taking strong CYP3A4 inhibitors or other medications that significantly lower heart rate.